I agree Our site saves small pieces of text information (cookies) on your device in order to deliver better content and for statistical purposes. You can disable the usage of cookies by changing the settings of your browser. By browsing our website without changing the browser settings you grant us permission to store that information on your device.
In 2017 PHENOMIN experts and teams have been integrated in 8 new research programs and partnerships: AXENIS partnership, PAIN-Net, TheraHCC, ANR projects (COSMIT, Enterocyte purge recovery, NACID), ERC project.
These projects complete the list of active PHENOMIN projects and partnerships: CELPHEDIA, INFRAFRONTIER, IMPC, CanPathPro, CRL partnership, ImmGen, Magenta, Marseille Immunopole, MSDAVENIR, Fondation Maladies Rares, Fondation Bettencourt Schuller, Fondation Jerome Lejeune.
Neuronal and Astroglial contribution to intellectual disability
ENTEROCYTE_PURGE_RECOVERY: Toxin and xenobiotics-inuced purge and subsequent recovery of enterocytes
European Framework Programme H2020 supports CanPathPro project, a unique and innovative platform for predictive modelling of cancer signaling.
CELPHEDIA (Creation, Breeding, Phenotyping, Distribution and Archiving of model organisms)
Integrated PHENOMIN-Charles River tool-box for Model Creation Services in Europe: ES Cell-Targeted Transgenesis, CRISPR/Cas9 Genome Editing, Random DNA Insertion.
Causative mechanisms & integrative models linking early-life-stress to psycho-cardio-metabolic multi-morbidity: EarlyCause will identify and demonstrate causative mechanisms and molecular pathways linking early life stress (ELS) to depression and two of its main physical comorbidities, namely coronary heart disease and diabetes.
EMMA: European Mouse Mutant Archive
EUCOMMTOOLS: EUCOMM Tools for Functional Annotation of the Mouse Genome
Fondation Maladies Rares
Gene overdosage and comorbidities during the early lifetime in Down Syndrome: The EU-funded GO-DS21 project is investigating the genetic mechanisms of this comorbidity. Outcomes should benefit patients with Down's syndrome and the general population.
IKMC: International Knock-Out Consortium
IMPC: International Mouse Phenotyping Consortium
Towards enduring mouse resources and services advancing research into human health and disease
Personalized MECP2 gene therapy using CRISPR/Cas9 technology coupled to AAV-mediated delivery in 3D cell culture and KI mice
Precision PathoBiology for Disease Models
TEFOR: Innovative services and tools for research on Drosophilia, Zebrafish and other model organisms.
AgedBrainSYSBIO - System biology of pathways involving brain aging
BPI FRANCE MAGENTA: Innovative animal models for the discovery of candidate genes to the validation of therapeutic molecules for genito-urinary disorders
CASIMIR: Coordination and Sustainability of International Mouse Informatics Resources
CREATE: Coordination of resources for conditional expression of mutated mouse alleles
EMTRAIN: European Medicines Research Training Network
EUCOMM: European Conditional Mouse Genetic Engineering and Model Validation Program
EUGENE2: European Network on Functional Genomics of Type 2 Diabetes
EUMODIC: The European Mouse Disease Clinic - A distributed phenotyping resource for studying human disease
EUMORPHIA: Understanding Human Disease Through Mouse Genetics
Eurexpress: A Transcriptome Atlas Database for Mouse Embryo
EVGN: European Vascular Genomics Network
Gencodys: Genetic and Epigenetic Networks in Cognitive Dysfunction
InfraCoMP: EC-funded initiative to coordinate the efforts of Infrafrontier and the IMPC
Infrafrontier: The European infrastructure for phenotyping and archiving of model mammmalian genomes
INTERREG IV Rhin superieur
RIGHT: RNA Interference Technology as Human Therapeutic Tool
Hepatocellular carcinoma – from molecular pathogenesis to clinical management The project is funded by the French ARC foundation and managed by the LabEx HepSYS to provide new targets for prevention and treatment of Hepatocellular carcinoma (HCC), relevant biological models of the disease, nanocarriers for personalized treatment and optimized clinical care protocols.